Although the U.S. Bankruptcy Court approved the OxyContin maker’s reorganization plan that freed the Sacklers from greater financial accountability and shielded them from additional lawsuits, the Department of Justice moved to block the Purdue Pharma bankruptcy deal.

A U.S. appeals court on Aug. 26 threw out a $1.2 billion ruling against Gilead Sciences Inc., finding a patent on a cancer therapy the company was accused of infringing was invalid, in a blow to rival Bristol Myers Squibb Co.

The Securities and Exchange Commission (SEC) is charging Matthew Panuwat – a former business development executive at Medivation – with insider trading, according to a complaint filed in court stemming from Pfizer’s acquisition of Medivation in 2016.

A federal appeals court on Aug. 16 revived nearly 6,000 lawsuits alleging that a widely used device produced by 3M Co. to keep surgical patients warm caused them to develop infections.

In a patent infringement lawsuit filed against Eli Lilly, Teva Pharmaceutical won three and lost six patents. The patent lawsuit was over Teva’s Ajovy (fremanezumab-vfrm) to prevent migraines. Eli Lilly has a competitive migraine drug, Emgality (galcanezumab).

A U.S. appeals court on Aug. 10 threw out a price-fixing lawsuit against two Chinese companies that make vitamin C, a case that spotlighted trade tensions between the United States and China.

Novartis AG wants Roche Holding AG to return $210 million after accusing the company’s Swiss rival of inappropriately pocketing fees from a 16-year-old patent licensing agreement, according to a lawsuit in U.S. District Court.

The U.S. Supreme Court rejected a bid by Johnson & Johnson to overturn a $70 million jury verdict against the pharmaceutical company for J&J’s failure to warn about risks associated with off-label uses of the antipsychotic drug Risperdal.

A U.S. judge granted a Reuters request to unseal Merck & Co. documents produced in lawsuits related to the company’s anti-baldness treatment Propecia, finding that the public’s right to access outweighed the drug maker’s arguments for keeping the information secret.

A federal appeals court upheld a White House-backed rule to require hospitals to disclose the prices they negotiate with insurers for an array of common tests and procedures.